Antitumor effect of adriamycin-encapsulated nanoparticles of poly(DL-lactide-co-glycolide)-grafted dextran

In this study, we prepared adriamycin (ADR)-encapsulated core–shell type nanoparticles of a poly(DL-lactide-co-glycolide) (PLGA) grafted-dextran (DexLG) copolymer and evaluated its antitumor activity in vitro and in vivo. The particle size of ADR-encapsulated DexLG nanoparticles was around 50–200nm...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical sciences 2009-06, Vol.98 (6), p.2104-2112
Main Authors: Choi, Ki-Choon, Bang, Je-Yong, Kim, Chan, Kim, Pyoung-Il, Lee, Sang-Rak, Chung, Wan-Tae, Park, Woo-Dae, Park, Jung-Sun, Lee, Yeon Soo, Song, Chae-Eun, Lee, Hye-Young
Format: Article
Language:English
Subjects:
adriamycin
Animals
Antibiotics, Antineoplastic - administration & dosage
Antibiotics, Antineoplastic - therapeutic use
Antibiotics, Antineoplastic - toxicity
Cell Line, Tumor
Cell Survival - drug effects
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
core-shell type nanoparticles
CT-26 colorectal tumor
dextran
Dextrans
Doxorubicin - administration & dosage
Doxorubicin - therapeutic use
Doxorubicin - toxicity
Drug Carriers
Freeze Drying
Humans
Lactic Acid
Mice
Mice, Inbred BALB C
Nanoparticles
Particle Size
poly(DL-lactide-co-glycolide)
Polyglycolic Acid
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study, we prepared adriamycin (ADR)-encapsulated core–shell type nanoparticles of a poly(DL-lactide-co-glycolide) (PLGA) grafted-dextran (DexLG) copolymer and evaluated its antitumor activity in vitro and in vivo. The particle size of ADR-encapsulated DexLG nanoparticles was around 50–200nm and the morphology was spherical shapes at transmission electron microscopy (TEM) observation. Since reconstitution of lyophilized nanoparticles is essential to practical use in vivo, ADR-encapsulated DexLG nanoparticles were lyophilized and reconstituted them into deionized water. Although reconstitution process caused increase of particle size, drug release behavior of nanoparticles was not significantly changed before and after reconstitution process. The ADR-encapsulated DexLG nanoparticles were less cytotoxic than free ADR plus empty nanoparticles at in vitro, while empty DexLG nanoparticles did not significantly affect cell viability. Even if free ADR plus empty nanoparticles are most effective to inhibit tumor growth at tumor-induced animal model using CT-26 cells, ADR-encapsulated DexLG nanoparticles showed increased survivability of mice. These results indicated that ADR-encapsulated DexLG nanoparticles are promising vehicles for antitumor drug delivery. © 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2104–2112, 2009
ISSN:0022-3549
1520-6017
DOI:10.1002/jps.21588